Triptoquinone A and B exercise a therapeutic effect in systemic lupus erythematosus by regulating NLRC3

The autoimmune disorder systemic lupus erythematosus (SLE) is multifaceted, with limited therapeutic alternatives and detrimental side effects, particularly on bones and joints. This research endeavors to examine the curative potential and underlying mechanisms of in addressing SLE-associated bone a...

Full description

Bibliographic Details
Main Authors: Qinyao Xu, Xiangzhi Zhang, Shangqing Ge, Chang Xu, Yuanfan Lv, Zongwen Shuai
Format: Article
Language:English
Published: PeerJ Inc. 2023-06-01
Series:PeerJ
Subjects:
Online Access:https://peerj.com/articles/15395.pdf
_version_ 1797423967920717824
author Qinyao Xu
Xiangzhi Zhang
Shangqing Ge
Chang Xu
Yuanfan Lv
Zongwen Shuai
author_facet Qinyao Xu
Xiangzhi Zhang
Shangqing Ge
Chang Xu
Yuanfan Lv
Zongwen Shuai
author_sort Qinyao Xu
collection DOAJ
description The autoimmune disorder systemic lupus erythematosus (SLE) is multifaceted, with limited therapeutic alternatives and detrimental side effects, particularly on bones and joints. This research endeavors to examine the curative potential and underlying mechanisms of in addressing SLE-associated bone and joint complications. Triptoquinone A and triptoquinone B, constituents of Tripterygium wilfordii polyglycoside tablets (TGTs), exhibit antioxidant and anti-inflammatory attributes; nonetheless, its function in SLE therapy remains elusive. This investigation delves into the role of oxidative stress in systemic lupus erythematosus (SLE) and probes the prospective remedial effects of triptoquinone A and triptoquinone B on inflammation and cartilage deterioration in SLE-affected joints. Employing bioinformatics analyses, differentially expressed genes (DEGs) and protein-protein interactions were discerned in SLE, rheumatoid arthritis (RA), and osteoarthritis (OA) datasets. Enrichment analyses unveiled shared genes implicated in immune system regulation and toll-like receptor signaling pathways, among others. Subsequent examination of triptoquinone A and triptoquinone B revealed their capacity to diminish NLRC3 expression in chondrocytes, resulting in decreased pro-inflammatory cytokine levels and cartilage degradation enzyme expression. Suppression of NLRC3 augmented the protective effects of triptoquinone A and B, implying that targeting NLRC3 may constitute a potential therapeutic strategy for inflammation and cartilage degeneration-associated conditions in SLE patients. Our discoveries indicate that triptoquinone A and triptoquinone B may impede SLE progression via the NLRC3 axis, offering potential benefits for SLE-affected bone and joint health.
first_indexed 2024-03-09T07:55:30Z
format Article
id doaj.art-488bd2c99125496cbbb9b23ee268cf88
institution Directory Open Access Journal
issn 2167-8359
language English
last_indexed 2024-03-09T07:55:30Z
publishDate 2023-06-01
publisher PeerJ Inc.
record_format Article
series PeerJ
spelling doaj.art-488bd2c99125496cbbb9b23ee268cf882023-12-03T01:03:57ZengPeerJ Inc.PeerJ2167-83592023-06-0111e1539510.7717/peerj.15395Triptoquinone A and B exercise a therapeutic effect in systemic lupus erythematosus by regulating NLRC3Qinyao Xu0Xiangzhi Zhang1Shangqing Ge2Chang Xu3Yuanfan Lv4Zongwen Shuai5Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaDepartment of Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaDepartment of Internal Medicine, School Hospital of Anhui Medical University, Hefei, ChinaDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaThe autoimmune disorder systemic lupus erythematosus (SLE) is multifaceted, with limited therapeutic alternatives and detrimental side effects, particularly on bones and joints. This research endeavors to examine the curative potential and underlying mechanisms of in addressing SLE-associated bone and joint complications. Triptoquinone A and triptoquinone B, constituents of Tripterygium wilfordii polyglycoside tablets (TGTs), exhibit antioxidant and anti-inflammatory attributes; nonetheless, its function in SLE therapy remains elusive. This investigation delves into the role of oxidative stress in systemic lupus erythematosus (SLE) and probes the prospective remedial effects of triptoquinone A and triptoquinone B on inflammation and cartilage deterioration in SLE-affected joints. Employing bioinformatics analyses, differentially expressed genes (DEGs) and protein-protein interactions were discerned in SLE, rheumatoid arthritis (RA), and osteoarthritis (OA) datasets. Enrichment analyses unveiled shared genes implicated in immune system regulation and toll-like receptor signaling pathways, among others. Subsequent examination of triptoquinone A and triptoquinone B revealed their capacity to diminish NLRC3 expression in chondrocytes, resulting in decreased pro-inflammatory cytokine levels and cartilage degradation enzyme expression. Suppression of NLRC3 augmented the protective effects of triptoquinone A and B, implying that targeting NLRC3 may constitute a potential therapeutic strategy for inflammation and cartilage degeneration-associated conditions in SLE patients. Our discoveries indicate that triptoquinone A and triptoquinone B may impede SLE progression via the NLRC3 axis, offering potential benefits for SLE-affected bone and joint health.https://peerj.com/articles/15395.pdfTriptoquinoneSystemic lupus erythematosus (SLE)Oxidative stressInflammationApoptosisNLRC3
spellingShingle Qinyao Xu
Xiangzhi Zhang
Shangqing Ge
Chang Xu
Yuanfan Lv
Zongwen Shuai
Triptoquinone A and B exercise a therapeutic effect in systemic lupus erythematosus by regulating NLRC3
PeerJ
Triptoquinone
Systemic lupus erythematosus (SLE)
Oxidative stress
Inflammation
Apoptosis
NLRC3
title Triptoquinone A and B exercise a therapeutic effect in systemic lupus erythematosus by regulating NLRC3
title_full Triptoquinone A and B exercise a therapeutic effect in systemic lupus erythematosus by regulating NLRC3
title_fullStr Triptoquinone A and B exercise a therapeutic effect in systemic lupus erythematosus by regulating NLRC3
title_full_unstemmed Triptoquinone A and B exercise a therapeutic effect in systemic lupus erythematosus by regulating NLRC3
title_short Triptoquinone A and B exercise a therapeutic effect in systemic lupus erythematosus by regulating NLRC3
title_sort triptoquinone a and b exercise a therapeutic effect in systemic lupus erythematosus by regulating nlrc3
topic Triptoquinone
Systemic lupus erythematosus (SLE)
Oxidative stress
Inflammation
Apoptosis
NLRC3
url https://peerj.com/articles/15395.pdf
work_keys_str_mv AT qinyaoxu triptoquinoneaandbexerciseatherapeuticeffectinsystemiclupuserythematosusbyregulatingnlrc3
AT xiangzhizhang triptoquinoneaandbexerciseatherapeuticeffectinsystemiclupuserythematosusbyregulatingnlrc3
AT shangqingge triptoquinoneaandbexerciseatherapeuticeffectinsystemiclupuserythematosusbyregulatingnlrc3
AT changxu triptoquinoneaandbexerciseatherapeuticeffectinsystemiclupuserythematosusbyregulatingnlrc3
AT yuanfanlv triptoquinoneaandbexerciseatherapeuticeffectinsystemiclupuserythematosusbyregulatingnlrc3
AT zongwenshuai triptoquinoneaandbexerciseatherapeuticeffectinsystemiclupuserythematosusbyregulatingnlrc3